|
Parkinson Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven (31.8%) Parkinson's disease patients developed neuropsychiatric complications (psychosis and delirium) after STN-DBS implantation surgery with full recovery in short follow up.
|
30267364 |
2020 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to examine whether postoperative stimulation challenge tests (SCT) alters patients' satisfaction after STN DBS for PD.
|
31665685 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
It was previously shown that bilateral, but not unilateral, subthalamic nucleus deep brain stimulation (STN DBS) in people with PD further increases the prosaccade error rate on the antisaccade task.
|
31455999 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical trials have established subthalamic deep-brain-stimulation (STN-DBS) as a highly effective treatment for motor symptoms of Parkinson disease (PD), but in clinical practice outcomes are variable.
|
30839077 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subthalamic deep brain stimulation (STN DBS) has been reported to improve the quality of life (QoL) related to Parkinson's disease (PD).
|
30451276 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was first to identify the influence of acute manipulation of STN-DBS in PD on the number and time pattern of word generation on different verbal fluency (VF) tasks, phonemic, switching, and cued switching, and second to determine whether cueing improved VF and if cueing effects interacted with STN-DBS effects.
|
31687126 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Subthalamic deep brain stimulation (STN DBS) programmed for treating PD motor symptoms has also been shown to significantly improve pain scores.
|
30898672 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The concept that subthalamic nucleus deep brain stimulation (STN DBS) may be disease modifying in Parkinson's disease (PD) is controversial.
|
30440081 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the influence of sex on the short-term and long-term effects of subthalamic nucleus stimulation (STN-DBS) in Parkinson's disease (PD) METHODS: We evaluated 48 male and 52 female PD patients enrolled in our prospective DBS registry who received bilateral STN-DBS between 2005 and 2013 and had 5-year follow-up data.
|
31621625 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bilateral STN DBS for Parkinson's disease is equally effective in young and elderly patients.
|
31481291 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the current study was to investigate the long-term effect of STN DBS on FOG in patients with PD.
|
30641837 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bilateral subthalamic nucleus deep brain stimulation (STN DBS) improves motor complications and quality of life (QOL) in patients with Parkinson's disease (PD).
|
31085861 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bilateral subthalamic nucleus deep brain stimulation (STN DBS) improves motor fluctuations and dyskinesias in patients with Parkinson's disease (PD).
|
31494731 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we summarized previous investigations focusing on STN-DBS influence on recognition of facial emotional expressions in patients suffering from PD.
|
31849760 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Motor response to and pre-surgical dosage of levodopa, male gender, and shorter PD duration were identified as predictors for posture improvement after STN DBS.
|
30638820 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that dopamine is partly involved in cost-benefit valuation, and that STN-DBS can have a beneficial effect on motivated behaviors in PD and may improve certain forms of impulsive behaviors.
|
30681186 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found different metabolic changes during DBS-STN among patients with PIGD, concerning brain regions that are already known to be involved in gait disorders in Parkinson's disease, suggesting that DBS is responsible for the appearance of PIGD.
|
31350641 |
2019 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whilst changes in the frequency of subthalamic deep brain stimulation (STN-DBS) have been proposed to improve control of tremor or axial motor features in Parkinson's disease (PD), little is known about the effects of frequency changes on upper limb motor function, particularly bradykinesia.
|
29614696 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nonetheless, we were able to discern subtle but distinct effects of PD and STN DBS in the emotional responses.
|
29936120 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
STN-DBS improves odor identification in a subset of patients with PD.
|
29548954 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This retrospective study aimed to evaluate the long-term effects of STN DBS on the PD motor subtypes.
|
30337863 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, little is known about the initial effects of STN-DBS on nonmotor domains.Our objective was to elucidate the initial effects of STN-DBS on non-motor and motor symptoms in PD patients in a 4-month follow-up.This open prospective study followed 24 patients with PD who underwent STN-DBS.
|
29384860 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deep brain stimulation of the subthalamic nucleus (STN DBS) is known to increase response speed and lower response accuracy in Parkinson's disease (PD) patients.
|
29458074 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion.</b> Our comparative study indicates that bilateral STN DBS is effective and can be used in patients with Parkinson disease with prior unilateral stereotactic destructive operations on subcortical structures.
|
29659494 |
2018 |
|
Parkinson Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Is bilateral STN DBS more, less, or as effective as bilateral GPi DBS in treating dyskinesias associated with Parkinson's disease?
|
29538685 |
2018 |